The Danish pharmaceutical company Novo Nordisk has increased its operating profit in the third quarter by 34 percent to DKK 21.902 million DKK increased (about EUR 2.94 million). The bottom line earned the world’s largest insulin producer DKK 15.677. The corresponding margin was 27.5 percent.
This was due to strong sales of diabetes drug Victoza, NovoRapid and Levemir, where sales increased to DKK 57.1 billion (+ 18 percent). In particular, the United States contributed to this sales growth of 30 percent.
[ilink url=“http://webmedia.novonordisk.com/nncom/images/investors/investor_presentations/2012/Interim_report/PR121031_Q3_2012_UK.pdf“] Link zur Quelle (Novo Nordirsk)[/ilink]